Abstract：
BACKGROUND: Coagulase negative Staphylococci (CoNS) are important. The common antibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin, clindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinone group of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of serious infections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci, vancomycin-resistant enterococci (VRE).
OBJECTIVE: This study emphasizes on the judicious use of newer antibiotics to contain the spread of resistance.
METHODS: We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which were reported in our laboratory during one year from patients with device related infections and also review of literature is being presented for an update.
RESULTS: In our study, the isolates were resistant to other groups of antimicrobials but susceptible to glycopeptides. All the isolates were methicillin-resistant.
CONCLUSIONS: Linezolid is approved as an alternative drug to be given for catheter-related bloodstream infections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly all over the world. This study is to create awareness amongst clinicians that improper and excessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future, so judicious and relevant use of antibiotics needs to be emphasized.
OBJECTIVE: This study emphasizes on the judicious use of newer antibiotics to contain the spread of resistance.
METHODS: We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which were reported in our laboratory during one year from patients with device related infections and also review of literature is being presented for an update.
RESULTS: In our study, the isolates were resistant to other groups of antimicrobials but susceptible to glycopeptides. All the isolates were methicillin-resistant.
CONCLUSIONS: Linezolid is approved as an alternative drug to be given for catheter-related bloodstream infections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly all over the world. This study is to create awareness amongst clinicians that improper and excessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future, so judicious and relevant use of antibiotics needs to be emphasized.
摘要：
背景：凝固酶阴性葡萄球菌（CoNS）很重要。用于治疗由CoNS引起的感染的常见抗生素是青霉素，苯唑西林,环丙沙星,克林霉素,红霉素,庆大霉素,和万古霉素.利奈唑胺是一种恶唑烷酮类抗生素，具有抗革兰氏阳性细菌的活性。它用于治疗由对其他抗生素耐药的革兰氏阳性菌引起的严重感染，包括链球菌,耐万古霉素肠球菌(VRE)。
目的：本研究强调合理使用新型抗生素以遏制耐药性的传播。
方法：我们正在讨论5例利奈唑胺耐药溶血葡萄球菌病例，这些病例在我们的实验室中报告了一年内来自器械相关感染患者的病例，并且正在进行文献综述以进行更新。
结果：在我们的研究中，这些分离株对其他类抗微生物药物有耐药性,但对糖肽敏感.所有分离株均耐甲氧西林。
结论：利奈唑胺被批准为导管相关性血流感染的替代药物。在早期的研究中，利奈唑胺耐药葡萄球菌在世界各地的报道越来越多。这项研究是为了提高临床医生的认识，即不当和过度使用利奈唑胺会使这种抗生素产生耐药性，因此在未来将无济于事。因此，需要强调明智和相关的抗生素使用。
目的：本研究强调合理使用新型抗生素以遏制耐药性的传播。
方法：我们正在讨论5例利奈唑胺耐药溶血葡萄球菌病例，这些病例在我们的实验室中报告了一年内来自器械相关感染患者的病例，并且正在进行文献综述以进行更新。
结果：在我们的研究中，这些分离株对其他类抗微生物药物有耐药性,但对糖肽敏感.所有分离株均耐甲氧西林。
结论：利奈唑胺被批准为导管相关性血流感染的替代药物。在早期的研究中，利奈唑胺耐药葡萄球菌在世界各地的报道越来越多。这项研究是为了提高临床医生的认识，即不当和过度使用利奈唑胺会使这种抗生素产生耐药性，因此在未来将无济于事。因此，需要强调明智和相关的抗生素使用。
